Dermal fillers in aesthetics: An overview of adverse events and treatment approaches

Clinical, Cosmetic and Investigational Dermatology

Volumn 6, Issue , 2013, Pages 295-316

  Funt, David ^a   Pavicic, Tatjana ^b  

^a MOUNT SINAI HOSPITAL   (United States)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

Aesthetic medicine; Complications

Indexed keywords

ACETYLSALICYLIC ACID; ANTACID AGENT; ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; BELOTERO; COLLAGEN; DERMAL FILLER; ENOXAPARIN; FILLER; FLUOROURACIL; GLYCERYL TRINITRATE; HYALURONIC ACID; HYALURONIDASE; HYDROQUINONE; IMMUNOGLOBULIN E; ISOTRETINOIN; LIDOCAINE; MACROLANE; METHYLPREDNISOLONE; MONTELUKAST; PREDNISONE; PREVELLE SILK; RETINOIC ACID; SILDENAFIL; STEROID; TETRACYCLINE; TRIAMCINOLONE; UNCLASSIFIED DRUG; VALACICLOVIR; VITAMIN K GROUP;

ABSCESS; ANGIONEUROTIC EDEMA; BIOFILM; CRYOTHERAPY; DELAYED HYPERSENSITIVITY; DRUG DOSE REDUCTION; DYE LASER; DYSPIGMENTATION; ERYSIPELAS; ERYTHEMA; ESTHETIC SURGERY; FOREIGN BODY GRANULOMA; HERPES VIRUS INFECTION; HUMAN; HYPERBARIC OXYGEN; HYPERPIGMENTATION; INFECTION; INJECTION SITE CONTUSION; MALAR EDEMA; NEOVASCULARIZATION (PATHOLOGY); PARESTHESIA; PERIORBITAL EDEMA; PHLEGMON; PIGMENT DISORDER; POSTOPERATIVE EDEMA; POTASSIUM TITANYL PHOSPHATE LASER; RETINA ARTERY OCCLUSION; REVIEW; SKIN BRUISING; SKIN NODULE; THERAPY EFFECT; TISSUE NECROSIS; TREATMENT INDICATION;

EID: 84890306366     PISSN: 11787015     EISSN: None     Source Type: Journal    
DOI: 10.2147/CCID.S50546     Document Type: Review

References (70)

1. American Society for Aesthetic Plastic Surgery. Cosmetic surgery national data bank statistics 2012. Available from: http://www.surgery.org/sites/default/files/ASAPS-2011-Stats.pdf. Accessed September 13, 2013.
2. Rzany B, Hilton S, Prager W, et al. Expert guideline on the use of porcine collagen in aesthetic medicine. J Dtsch Dermatol Ges. 2010;8(3): 210-217.
3. Goldberg DJ. Legal ramifications of off-label filler use. Dermatol Ther. 2006;19(3):189-193.
4. Glogau RG, Kane MA. Effect of injection techniques on the rate of local adverse events in patients implanted with nonanimal hyaluronic acid gel dermal fillers. Dermatol Surg. 2008;34 Suppl 1:S105-S109.
5. Zielke H, Wölber L, Wiest L, Rzany B. Risk profiles of different injectable fillers: results from the Injectable Filler Safety Study (IFS Study). Dermatol Surg. 2008;34(3):326-335.
6. Narins RS, Brandt FS, Lorenc ZP, Maas CS, Monheit GD, Smith SR. Twelve-month persistency of a novel ribose-cross-linked collagen dermal filler. Dermatol Surg. 2008;34 Suppl 1:S31-S39.
7. Bass LS, Smith S, Busso M, McClaren M. Calcium hydroxylapatite (Radiesse) for treatment of nasolabial folds: long-term safety and efficacy results. Aesthet Surg J. 2010;30(2):235-238.
8. Fitzgerald R, Vleggaar D. Facial volume restoration of the aging face with poly-l-lactic acid. Dermatol Ther. 2011;24(1):2-27.
9. Hilinski JM, Cohen SR. Soft tissue augmentation with ArteFill. Facial Plast Surg. 2009;25(2):114-119.
10. Pallua N, Wolter TP. A 5-year assessment of safety and aesthetic results after facial soft-tissue augmentation with polyacrylamide hydrogel (Aquamid): a prospective multicenter study of 251 patients. Plast Reconstr Surg. 2010;125(6):1797-1804.
11. Gladstone HB, Cohen JL. Adverse effects when injecting facial fillers. Semin Cutan Med Surg. 2007;26(1):34-39.
12. Shah NS, Lazarus MC, Bugdodel R, et al. The effects of topical vitamin K on bruising after laser treatment. J Am Acad Dermatol. 2002;47(2):241-244.
13. Bailey SH, Cohen JL, Kenkel JM. Etiology, prevention, and treatment of dermal filler complications. Aesthet Surg J. 2011;31(1):110-121.
14. Zeichner JA, Cohen JL. Use of blunt tipped cannulas for soft tissue fillers. J Drugs Dermatol. 2012;11(1):70-72.
15. Van Dyke S, Hays GP, Caglia AE, Caglia M. Severe Acute Local Reactions to a Hyaluronic Acid-derived Dermal Filler. J Clin Aesthet Dermatol. 2010;3(5):32-35.
16. Geisler D, Shumer S, Elson ML. Delayed hypersensitivity reaction to Restylane®. Cosmetic Dermatol. 2007;20(12):784-786.
17. Arron ST, Neuhaus IM. Persistent delayed-type hypersensitivity reaction to injectable non-animal-stabilized hyaluronic acid. J Cosmet Dermatol. 2007;6(3):167-171.
18. Cassuto D, Marangoni O, De Santis G, Christensen L. Advanced laser techniques for filler-induced complications. Dermatol Surg. 2009;35 Suppl 2:1689-1695.
19. Funt DK. Avoiding malar edema during midface/cheek augmentation with dermal fillers. J Clin Aesthet Dermatol. 2011;4(12):32-36.
20. Griepentrog GJ, Lucarelli MJ, Burkat CN, Lemke BN, Rose JG. Periorbital edema following hyaluronic acid gel injection: a retrospective review. Am J Cosmetic Surg. 2011;28(4):251-254.
21. Pessa JE, Garza JR. The malar septum: the anatomic basis of malar mounds and malar edema. Aesthet Surg J. 1997;17(1):11-17.
22. Cohen JL, Bhatia AC. The role of topical vitamin K oxide gel in the resolution of postprocedural purpura. J Drugs Dermatol. 2009;8(11): 1020-1024.
23. Taylor SC, Burgess CM, Callender VD. Safety of nonanimal stabilized hyaluronic acid dermal fillers in patients with skin of color: a randomized, evaluator-blinded comparative trial. Dermatol Surg. 2009;35 Suppl 2:1653-1660.
24. Heath CR, Taylor SC. Fillers in the skin of color population. J Drugs Dermatol. 2011;10(5):494-498.
25. Pavicic T. Efficacy and tolerability of a new monophasic, double-crosslinked hyaluronic acid filler for correction of deep lines and wrinkles. J Drugs Dermatol. 2011;10(2):134-139.
26. Hirsch RJ, Narurkar V, Carruthers J. Management of injected hyaluronic acid induced Tyndall effects. Lasers Surg Med. 2006; 38(3):202-204.
27. Douse-Dean T, Jacob CI. Fast and easy treatment for reduction of the Tyndall effect secondary to cosmetic use of hyaluronic acid. J Drugs Dermatol. 2008;7(3):281-283.
28. Rousso JJ, Pitman MJ. Enterococcus faecalis complicating dermal filler injection: a case of virulent facial abscesses. Dermatol Surg. 2010; 36(10):1638-1641.
29. Sclafani AP, Fagien S. Treatment of injectable soft tissue filler complications. Dermatol Surg. 2009;35(Suppl 2):1672-1680.
30. Voigts R, Devore DP, Grazer JM. Dispersion of calcium hydroxylapatite accumulations in the skin: animal studies and clinical practices. Dermatol Surg. 2010;36(Suppl s1):798-803.
31. Vrcek IM, Malouf P, Gilliland GD. A novel solution for superficially placed calcium hydroxylapatite (Radiesse) in the inferior eyelid. Orbit. 2012;31(6):431-432.
32. Reddy KK, Brauer JA, Anolik R, et al. Calcium hydroxylapatite nodule resolution after fractional carbon dioxide laser therapy. Arch Dermatol. 2012;148(5):634-636.
33. Heinz BC, Ladhoff U, Kahl Ch, Rzany B, von Mallek D. [Survey of incidents associated with injectable dermal fillers reported to the German Medical Devices Vigilance System]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2008;51(7):787-792. German.
34. Christensen LH. Host tissue interaction, fate, and risks of degradable and nondegradable gel fillers. Dermatol Surg. 2009;35 Suppl 2:1612-1619.
35. Monheit GD, Rohrich RJ. The nature of long-term fillers and the risk of complications. Dermatol Surg. 2009;35 Suppl 2:1598-1604.
36. Narins RS, Coleman WP, Glogau RG. Recommendations and treatment options for nodules and other filler complications. Dermatol Surg. 2009;35 Suppl 2:1667-1671.
37. Dayan SH, Arkins JP, Brindise R. Soft tissue fillers and biofilms. Facial Plast Surg. 2011;27(1):23-28.
38. Bjarnsholt T, Tolker-Nielsen T, Givskov M, Janssen M, Christensen LH. Detection of bacteria by fluorescence in situ hybridization in culture-negative soft tissue filler lesions. Dermatol Surg. 2009;35 Suppl 2:1620-1624.
39. Grippaudo FR, Pacilio M, Di Girolamo M, Dierckx RA, Signore A. Radiolabelled white blood cell scintigraphy in the work-up of dermal filler complications. Eur J Nucl Med Mol Imaging. 2013;40(3): 418-425.
40. Alijotas-Reig J, Fernández-Figueras MT, Puig L. Late-onset inflammatory adverse reactions related to soft tissue filler injections. Clin Rev Allergy Immunol. 2013;45(1):97-108.
41. Lemperle G, Gauthier-Hazan N, Wolters M, Eisemann-Klein M, Zimmermann U, Duffy DM. Foreign body granulomas after all injectable dermal fillers: part 1. Possible causes. Plast Reconstr Surg. 2009;123(6):1842-1863.
42. Lemperle G, Gauthier-Hazan N. Foreign body granulomas after all injectable dermal fillers: part 2. Treatment options. Plast Reconstr Surg. 2009;123(6):1864-1873.
43. Alijotas-Reig J, Garcia-Gimenez V, Miró-Mur F, Vilardell-Tarrés M. Delayed immune-mediated adverse effects of polyalkylimide dermal fillers: clinical findings and long-term follow-up. Arch Dermatol. 2008;144(5):637-642.
44. Chrastil-LaTowsky B, Wesley NO, MacGregor JL, Kaminer MS, Arndt KA. Delayed inflammatory reaction to bio-alcamid polyacrylamide gel used for soft-tissue augmentation. Arch Dermatol. 2009;145(11): 1309-1312.
45. Sachdev M, Anantheswar Y, Ashok B, Hameed S, Pai SA. Facial granulomas secondary to injection of semi-permanent cosmetic dermal filler containing acrylic hydrogel particles. J Cutan Aesthet Surg. 2010; 3(3):162-166.
46. Descamps V, Landry J, Francès C, Marinho E, Ratziu V, Chosidow O. Facial cosmetic filler injections as possible target for systemic sarcoidosis in patients treated with interferon for chronic hepatitis C: two cases. Dermatology (Basel). 2008;217(1):81-84.
47. Dammak A, Taillé C, Marinho E, Crestani B, Crickx B, Descamps V. Granulomatous foreign-body reaction with facial dermal fillers after omalizumab treatment for severe persistent allergic asthma: a case report. Br J Dermatol. 2012;166(6):1375-1376.
48. Wiest LG, Stolz W, Schroeder JA. Electron microscopic documentation of late changes in permanent fillers and clinical management of granulomas in affected patients. Dermatol Surg. 2009;35 Suppl 2:1681-1688.
49. Brody HJ. Use of hyaluronidase in the treatment of granulomatous hyaluronic acid reactions or unwanted hyaluronic acid misplacement. Dermatol Surg. 2005;31(8 Pt 1):893-897.
50. Kwon SG, Hong JW, Roh TS, Kim YS, Rah DK, Kim SS. Ischemic oculomotor nerve palsy and skin necrosis caused by vascular embolization after hyaluronic Acid filler injection: a case report. Ann Plast Surg. 2013;71(4):333-334.
51. Peter S, Mennel S. Retinal branch artery occlusion following injection of hyaluronic acid (Restylane). Clin Experiment Ophthalmol. 2006; 34(4):363-364.
52. Kim YJ, Kim SS, Song WK, Lee SY, Yoon JS. Ocular ischemia with hypotony after injection of hyaluronic acid gel. Ophthal Plast Reconstr Surg. 2011;27(6):e152-e155.
53. Grunebaum LD, Bogdan Allemann I, Dayan S, Mandy S, Baumann L. The risk of alar necrosis associated with dermal filler injection. Dermatol Surg. 2009;35 Suppl 2:1635-1640.
54. Schanz S, Schippert W, Ulmer A, Rassner G, Fierlbeck G. Arterial embolization caused by injection of hyaluronic acid (Restylane). Br J Dermatol. 2002;146(5):928-929.
55. Coleman SR. Avoidance of arterial occlusion from injection of soft tissue fillers. Aesthet Surg J. 2002;22(6):555-557.
56. Feinendegen DL, Baumgartner RW, Vuadens P, et al. Autologous fat injection for soft tissue augmentation in the face: a safe procedure? Aesthetic Plast Surg. 1998;22(3):163-167.
57. Egido JA, Arroyo R, Marcos A, Jiménez-Alfaro I. Middle cerebral artery embolism and unilateral visual loss after autologous fat injection into the glabellar area. Stroke. 1993;24(4):615-616.
58. Lee DH, Yang HN, Kim JC, Shyn KH. Sudden unilateral visual loss and brain infarction after autologous fat injection into nasolabial groove. Br J Ophthalmol. 1996;80(11):1026-1027.
59. Thaunat O, Thaler F, Loirat P, Decroix JP, Boulin A. Cerebral fat embolism induced by facial fat injection. Plast Reconstr Surg. 2004;113(7): 2235-2236.
60. Yoon SS, Chang DI, Chung KC. Acute fatal stroke immediately following autologous fat injection into the face. Neurology. 2003;61(8): 1151-1152.
61. Silva MT, Curi AL. Blindness and total ophthalmoplegia after aesthetic polymethylmethacrylate injection: case report. Arq Neuropsiquiatr. 2004;62(3B):873-874.
62. Dayan SH, Arkins JP, Mathison CC. Management of impending necrosis associated with soft tissue filler injections. J Drugs Dermatol. 2011;10(9):1007-1012.
63. Hirsch RJ, Cohen JL, Carruthers JD. Successful management of an unusual presentation of impending necrosis following a hyaluronic acid injection embolus and a proposed algorithm for management with hyaluronidase. Dermatol Surg. 2007;33(3):357-360.
64. Bachmann F, Erdmann R, Hartmann V, Wiest L, Rzany B. The spectrum of adverse reactions after treatment with injectable fillers in the glabellar region: results from the Injectable Filler Safety Study. Dermatol Surg. 2009;35 Suppl 2:1629-1634.
65. Georgescu D, Jones Y, McCann JD, Anderson RL. Skin necrosis after calcium hydroxylapatite injection into the glabellar and nasolabial folds. Ophthal Plast Reconstr Surg. 2009;25(6):498-499.
66. Kassir R, Kolluru A, Kassir M. Extensive necrosis after injection of hyaluronic acid filler: case report and review of the literature. J Cosmet Dermatol. 2011;10(3):224-231.
67. Glaich AS, Cohen JL, Goldberg LH. Injection necrosis of the glabella: protocol for prevention and treatment after use of dermal fillers. Dermatol Surg. 2006;32(2):276-281.
68. Burt B, Nakra T, Isaacs DK, Goldberg RA. Alar necrosis after facial injection of hyaluronic Acid. Plast Reconstr Surg. 2010;125(5): 199e-200e.
69. Kleydman K, Cohen JL, Marmur E. Nitroglycerin: a review of its use in the treatment of vascular occlusion after soft tissue augmentation. Dermatol Surg. 2012;38(12):1889-1897.
70. Lowe NJ, Maxwell CA, Patnaik R. Adverse reactions to dermal fillers: review. Dermatol Surg. 2005;31(11 Pt 2):1616-1625.